Generated by AI
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious disease, with particular emphasis on chronic hepatitis B virus infection. Arbutus Biopharma Corporation is developing imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered RNA interference therapeutic, and AB-101, an oral PD-L1 inhibitor, both designed to target different aspects of HBV biology and immune response. The company’s work centers on advancing virology-based therapies that may contribute to improved treatment options for patients living with chronic hepatitis B. Arbutus Biopharma Corporation operates within the broader biotechnology sector, where its current programs, proprietary drug candidates, and infectious-disease focus position it as a specialized developer of novel therapeutics.
Website701 Veterans Circle
Warminster, PA, 18974
United States
The latest articles about ABUS.
Arbutus Biopharma is a Buy, leveraging a $179.1M Moderna settlement and a 46M share buyback to enhance per-share value. Click for more on ABUS stock.
Summary of Nov 16's posts. Generated by AI.
Summary of Aug 21's posts. Generated by AI.
WARMINSTER, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced the final results of its tender offer (the “Offer”) to purchase for cancellation up to US$230 million in value of its common shares (the “Shares”). The Offer proceeded by way of a modified Dutch auction, which had a tender price range from US$5.00 per Share to US$5.75 per Share, and
Summary of Jul 27's posts. Generated by AI.
Summary of Aug 21's posts. Generated by AI.
Investors talking about ABUS also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.